Dredge, Keith <br/><br/>
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.  [electronic resource] 

 -  Microvascular research  Jan 2005 
 - 56-63 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0026-2862 
<br/><br/><label>Standard No.: </label>10.1016/j.mvr.2005.01.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Angiogenesis Inhibitors--pharmacology<br/>Animals<br/>Area Under Curve<br/>Cell Movement--drug effects<br/>Dose-Response Relationship, Drug<br/>Endothelium, Vascular--cytology<br/>Humans<br/>Kinetics<br/>Lenalidomide<br/>Male<br/>Mesentery--blood supply<br/>Phosphorylation--drug effects<br/>Protein Serine-Threonine Kinases--metabolism<br/>Proto-Oncogene Proteins--metabolism<br/>Proto-Oncogene Proteins c-akt<br/>Rats<br/>Rats, Sprague-Dawley<br/>Thalidomide--administration & dosage<br/>Umbilical Veins--cytology